Panel discussion: past, present and future of immuno-oncology

This panel discussion, featuring experts from institutions across the world, will focus on the key challenges outstanding in the field of immuno-oncology. It aims to assess promising new immunotherapy targets and strategies, and will discuss experts’ predictions on how COVID-19 will impact cancer research long-term.

What will you learn?

  • Regulatory perspectives on immuno-oncology trials and approvals
  • How to manage toxicities and incorporate biomarkers into therapeutic decision making
  • Promising new immunotherapy combinations
  • The impact COVID-19 could have on response to immunotherapies

Who may this interest?

  • Researchers and clinicians working in the multidisciplinary field of immuno-oncology
  • Regulatory bodies
  • Oncology investors




Dario Vignali

Frank Dixon Chair in Cancer Immunology (University of Pittsburgh, PA, USA)

Vignali moved to the University of Pittsburgh to become Vice Chair and Professor of Immunology, and the UPMC Hillman Cancer Center to become Co-Leader of the Cancer Immunology Program and Co-Director of the Tumor Microenvironment Center. His research focuses on gaining a better understanding of the inhibitory mechanisms that limit anti-tumor immunity in cancer.


Aaron Sato

Chief Scientific Officer (Twist Biopharma; Twist Bioscience, CA, USA)

Aaron is a proven biologics leader adept at managing teams to discover and develop novel first-in-class antibody therapeutics. Prior to Twist Bioscience, he served as Chief Scientific Officer of LakePharma (CA, USA), leading the California Antibody Center. Prior to LakePharma, he oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma (both CA, USA).


Teri Heiland

Chief Scientific Officer (Immunomic Therapeutics, MD, USA)

Heiland is the Chief Scientific Officer at Immunomic Therapeutics and cofounder of the Company. She has over 20 years of senior industry leadership experience. Her primary focus and expertise is in DNA vaccine design, optimization and development. Heiland is also one of the founders of Capital Genomix (MD, USA), a biomarker and drug discovery Company and served as its VP of Research and Development until 2006.


Jarret Glasscock

Founder and CEO (Cofactor Genomics, MO, USA)

Jarret is a geneticist and computational biologist driven to translate ‘big data’ into meaningful biological signals using Predictive Immune Modeling. Prior to founding Cofactor Genomics in 2008, Jarret was faculty in the Department of Genetics at Washington University (MO, USA) and part of The Genome Institute. He was involved in the Human Genome Project and published the first Cancer Genome.


Marina Garassino

Chief of the Thoracic Oncology Unit (Instituto Nazionale dei Tumori, Milan, Italy)

Garassino leads the strategy for clinical and translational research in advanced and locally advanced NSCLC, mesothelioma and thymic malignancies at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, which is one the most important cancer centers in Italy, and in Europe. As a medical oncologist, she has done research in precision medicine and in immuno-oncology.


In association with: